Back to Top
Mariana Callero, PhD
-
May 17, 2026
Research Highlights | IL-11R Blockade in Fibro-Inflammatory Disease
... -
April 28, 2026
In the evolving landscape of cancer immunotherapy, the Major Histocompatibility Complex class I-related chain A and B (MICA/B) proteins have emerged as compelling targets. While their expression is induced by cellular stress, marking malignant cells for destruction by Natural Killer (NK) cells, tumors frequently evade this surveillance by proteolytically shedding MICA/B from their surface. This "molecular camouflage" not only reduces target density...
-
April 12, 2026
The landscape of biotherapeutic development is increasingly defined by the rigor of analytical comparability. In a recent study published in Biotechnology and Bioprocess Engineering, Lee et al. (2026) present a sophisticated MALDI-MS-based quantitative glycomics workflow that addresses long-standing challenges in N-glycan profiling. By utilizing ichorbio’s Etanercept Biosimilar...
-
March 09, 2026
Focused Ultrasound Thermal Ablation (T-FUS) and CD40 agonism in TNBC
The therapeutic landscape for breast cancer (BC) remains bifurcated by molecular subtypes. While triple-negative breast cancer (TNBC) has seen modest progress with immune checkpoint blockade (ICB), luminal (HR+) subtypes often present as "immunologically cold," characterized by low mutational...
-
February 17, 2026
By Mariana Callero, PhD.
Immune checkpoint blockade (ICB), particularly targeting the PD-1/PD-L1 axis, has redefined the treatment landscape for advanced gastric cancer (AGC). However, the clinical reality remains sobering: only approximately 15% of patients derive durable benefit from anti-PD-1 monotherapy. The majority of patients exhibit primary or adaptive...
-
February 04, 2026
The Goldilocks Solution: Uncoupling CD137 Agonism from Hepatotoxicity via Nanoparticle-Mediated Ligand Multimerization
The clinical history of CD137 (4-1BB) agonism is a tale of two extremes. On one side stands urelumab, an antibody with tremendous potency that failed due to severe, dose-limiting hepatotoxicity. On the other stands utomilumab, a molecule with...
-
December 22, 2025
The Phosphatase Factor: PPP2R2A Insufficiency Sensitizes NSCLC to PD-L1 Blockade via cGAS-STING Activation
The Genomic Stability-Immunity Axis
In the evolving landscape of cancer immunotherapy, the transition from "cold" to "hot" tumor microenvironments (TMEs) remains a primary therapeutic objective. A seminal paper recently published in...
-
December 20, 2025
Decoding the Mineralized Microenvironment: Autonomous Paracrine Signaling and High-Fidelity Drug Response in a Nanoscale Bone-on-a-Chip
For decades, the primary challenge in bone tissue engineering has been the "growth factor paradox." Standard in-vitro models typically rely on supraphysiological concentrations of recombinant proteins, such as RANKL and M-CSF...
-
December 16, 2025
Cytokine-Controlled Vulnerability: How TNF-α and IFN-γ Shape the Therapeutic Window for CD70-Targeted Immunotherapy in AML
How lirilumab (ICH4067) and monalizumab (ICH4071) exposed an IFN-γ–driven inhibitory shield that limits NK-cell immunotherapy
The promise of CD70-targeted therapies...
-
September 01, 2022
Researchers from the Dana-Farber Cancer Institute and Harvard Medical School have conducted a comprehensive comparison of commonly used monoclonal antibodies (mAbs) targeting the PD-1/PD-L1 pathway in mice. Their findings, recently published in the journal Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, provide valuable insights for modeling cancer immunotherapy in preclinical studies.
The PD-1/PD-L1 pathway is a critical immune...
